The global oral proteins and peptides market is undergoing rapid expansion, with its valuation reaching USD 9.50 billion in 2025 and projected to soar to USD 47.33 billion by 2035. This growth corresponds to a compound annual growth rate (CAGR) of approximately 17.42% during the forecast period from 2026 to 2035. This robust trajectory underscores the increasing adoption of oral protein and peptide formulations across healthcare, nutrition, and wellness domains.
A defining development shaping the market is the strategic repositioning of proteins and peptides as functional, bioactive agents rather than simple nutritional inputs. In 2025, industry leaders such as Nestlé Health Science and Danone advanced portfolio restructuring strategies aimed at bridging food and pharmaceutical applications. Their focus on enzymatic hydrolysis technologies has enabled the conversion of long-chain proteins into smaller, bioactive peptides with improved absorption potential and targeted physiological effects, reinforcing the market’s transition toward clinically relevant oral formulations.
A major development in 2025 was the intensified convergence between nutrition and pharmaceutical portfolios by companies such as Nestlé Health Science and Danone, which have invested heavily in enzymatic hydrolysis and functional peptide development. Parallel to this, supply-side constraints are being addressed through large-scale manufacturing investments. Between 2024 and 2025, Eli Lilly and Novo Nordisk collectively committed over USD 18 billion toward expanding peptide synthesis capacity in regions including North Carolina and Denmark. These investments are intended to stabilize global supply, shorten development timelines, and support the commercialization of next-generation oral peptide therapies.
Additionally, expanding consumer awareness around preventative healthcare and functional nutrition is reinforcing demand beyond traditional clinical settings. Oral proteins and peptides are increasingly being incorporated into daily health routines, further broadening their market reach across both medical and consumer-driven applications.
As a result, product development is increasingly centered on advanced delivery systems designed to protect peptides from enzymatic degradation and facilitate intestinal transport. These innovations are enabling more precise therapeutic and nutritional outcomes, creating new growth avenues across both prescription and over-the-counter segments.
Overcoming these constraints remains a central focus of industry research, with continued reliance on advanced excipients, carrier systems, and delivery enhancers to improve systemic absorption while maintaining molecular stability.
By Application, sports and performance nutrition leads the market with a 38.56% share, driven by its evolution into a broader “active nutrition” category appealing to non-athlete consumers.
By End User, sports and fitness enthusiasts represent the largest segment, capturing 41.67% of total revenue, supported by rising global participation in physical activity.
By Source, animal-derived proteins such as whey, casein, and collagen dominate with over 34% share due to superior amino acid profiles and bioavailability.
A notable example includes CordenPharma’s USD 500 million investment announced in July 2024 to expand its Colorado facility, strengthening North America’s position as a global hub for oral peptide development and production.
A defining development shaping the market is the strategic repositioning of proteins and peptides as functional, bioactive agents rather than simple nutritional inputs. In 2025, industry leaders such as Nestlé Health Science and Danone advanced portfolio restructuring strategies aimed at bridging food and pharmaceutical applications. Their focus on enzymatic hydrolysis technologies has enabled the conversion of long-chain proteins into smaller, bioactive peptides with improved absorption potential and targeted physiological effects, reinforcing the market’s transition toward clinically relevant oral formulations.
Noteworthy Market Developments
The oral proteins and peptides market is characterized by strong participation from established pharmaceutical and life sciences companies prioritizing oral alternatives to injectable therapies. These players are channeling substantial resources into research and development to address bioavailability limitations and enhance therapeutic outcomes through advanced formulation strategies.A major development in 2025 was the intensified convergence between nutrition and pharmaceutical portfolios by companies such as Nestlé Health Science and Danone, which have invested heavily in enzymatic hydrolysis and functional peptide development. Parallel to this, supply-side constraints are being addressed through large-scale manufacturing investments. Between 2024 and 2025, Eli Lilly and Novo Nordisk collectively committed over USD 18 billion toward expanding peptide synthesis capacity in regions including North Carolina and Denmark. These investments are intended to stabilize global supply, shorten development timelines, and support the commercialization of next-generation oral peptide therapies.
Core Growth Drivers
The rising global burden of chronic diseases such as diabetes, cancer, and gastrointestinal disorders is a fundamental driver of demand for oral protein and peptide therapies. Many of these conditions require prolonged treatment regimens, where injectable delivery methods negatively impact patient compliance and quality of life. Oral formulations offer a compelling alternative by reducing treatment burden while supporting long-term adherence.Additionally, expanding consumer awareness around preventative healthcare and functional nutrition is reinforcing demand beyond traditional clinical settings. Oral proteins and peptides are increasingly being incorporated into daily health routines, further broadening their market reach across both medical and consumer-driven applications.
Emerging Opportunity Trends
Targeted delivery technologies are emerging as a critical innovation frontier within the oral proteins and peptides market. The focus is shifting from maximizing protein dosage to optimizing absorption efficiency and site-specific delivery. This trend reflects growing recognition that clinical and functional efficacy is closely tied to bioavailability rather than intake volume.As a result, product development is increasingly centered on advanced delivery systems designed to protect peptides from enzymatic degradation and facilitate intestinal transport. These innovations are enabling more precise therapeutic and nutritional outcomes, creating new growth avenues across both prescription and over-the-counter segments.
Barriers to Optimization
Despite strong growth momentum, the market continues to face fundamental biological and technical challenges. The large molecular size and hydrophilic nature of proteins and peptides significantly limit their ability to cross the intestinal epithelium, resulting in low oral bioavailability. This barrier necessitates complex formulation strategies, which can increase development costs and prolong commercialization timelines.Overcoming these constraints remains a central focus of industry research, with continued reliance on advanced excipients, carrier systems, and delivery enhancers to improve systemic absorption while maintaining molecular stability.
Detailed Market Segmentation
By Product, nutritional proteins, including isolates, hydrolysates, and clinical formulations, account for over 48% of the market. Their dominance reflects successful expansion beyond sports supplementation into medical nutrition and preventive health applications.By Application, sports and performance nutrition leads the market with a 38.56% share, driven by its evolution into a broader “active nutrition” category appealing to non-athlete consumers.
By End User, sports and fitness enthusiasts represent the largest segment, capturing 41.67% of total revenue, supported by rising global participation in physical activity.
By Source, animal-derived proteins such as whey, casein, and collagen dominate with over 34% share due to superior amino acid profiles and bioavailability.
Segment Breakdown
By Product Type
- Nutritional Proteins
- Bioactive Peptides
- Therapeutic Peptides
By Source
- Animal-Derived Proteins
- Plant-Derived Proteins
- Synthetic/Fermentation-Derived Peptides
- Collagen-Derived Peptides
By Application
- Sports & Performance Nutrition
- Weight Management
- Immune Health Support
- Digestive & Gut Health
- Bone & Joint Health
- Metabolic Health
- Therapeutic/Clinical Nutrition
- Other Functional Applications
By End-User
- Sports & Fitness Enthusiasts
- Health & Wellness Consumers
- Medical & Clinical Nutrition Patients
- Aging Population / Elderly
- Lifestyle / Weight Management Users
By Region
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- South America
Geographical Breakdown
North America leads the global oral proteins and peptides market with a 38.23% share, supported by aggressive capital investment, advanced clinical validation infrastructure, and a regulatory environment conducive to chronic disease management. Regional dominance is reinforced by substantial manufacturing investments aimed at securing supply resilience and accelerating product development.A notable example includes CordenPharma’s USD 500 million investment announced in July 2024 to expand its Colorado facility, strengthening North America’s position as a global hub for oral peptide development and production.
Leading Market Participants
- AbbVie Inc.
- Biocon Limited
- Chiesi Farmaceutici S.p.A.
- EnteraBio Ltd.
- Groupe Sanofi
- Johnson & Johnson Services, Inc.
- Novo Nordisk A/S
- Oramed Pharmaceuticals Inc.
- Pfizer Inc.
- Proxima Concepts
- Synergy Pharma
- Tarsa Therapeutics, Inc.
- Other Prominent Players
Table of Contents
Chapter 1. Executive Summary: Oral Protein and Peptides Market
Chapter 2. Report Description
Chapter 3. Oral Protein and Peptides Market Overview
Chapter 4. Competition Dashboard
Chapter 5. Oral Protein And Peptides Market Analysis
Chapter 6. North America Oral Protein And Peptides Market Analysis
Chapter 7. Europe Oral Protein And Peptides Market Analysis
Chapter 8. Asia Pacific Oral Protein And Peptides Market Analysis
Chapter 9. Middle East & Africa Oral Protein And Peptides Market Analysis
Chapter 10. South America Oral Protein And Peptides Market Analysis
Chapter 11. Company Profiles (Company Overview, Company Timeline, Organization Structure, Key Product landscape, Financial Matrix, Key Customers/Sectors, Key Competitors, SWOT Analysis, Contact Address, and Business Strategy Outlook)
Chapter 12. Annexure
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- AbbVie Inc.
- Biocon Limited
- Chiesi Farmaceutici S.p.A.
- Entera Bio Ltd.
- Groupe Sanofi
- Johnson & Johnson Services, Inc.
- Novo Nordisk A/S
- Oramed Pharmaceuticals Inc.
- Pfizer Inc.
- Proxima Concepts
- Synergy Pharma
- Tarsa Therapeutics, Inc.
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 280 |
| Published | January 2026 |
| Forecast Period | 2025 - 2035 |
| Estimated Market Value ( USD | $ 9.5 Billion |
| Forecasted Market Value ( USD | $ 47.33 Billion |
| Compound Annual Growth Rate | 17.4% |
| Regions Covered | Global |
